Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?

EGFR tyrosine-kinase inhibitors (TKIs) have now been firmly established as the first-line treatment for non-small-cell lung cancer (NSCLC) patients harboring activating EGFR mutations, based on seven prospective randomized Phase III trials. However, despite significantly improved overall response ra...

Full description

Saved in:
Bibliographic Details
Published in:Drug Des Devel Ther
Main Authors: Ou, Sai-Hong Ignatius, Soo, Ross A
Format: Artigo
Language:Inglês
Published: Dove Medical Press 2015
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4610796/
https://ncbi.nlm.nih.gov/pubmed/26508839
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S52787
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items